BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37375350)

  • 1. Discovery of a Potent Highly Biased MOR Partial Agonist among Diastereomeric C9-Hydroxyalkyl-5-phenylmorphans.
    Lutz JA; Sulima A; Gutman ES; Bow EW; Luo D; Kaska S; Prisinzano TE; Paronis CA; Bergman J; Imler GH; Kerr AT; Jacobson AE; Rice KC
    Molecules; 2023 Jun; 28(12):. PubMed ID: 37375350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional Activity of Enantiomeric Oximes and Diastereomeric Amines and Cyano Substituents at C9 in 3-Hydroxy-
    Roth HG; Das M; Sulima A; Luo D; Kaska S; Prisinzano TE; Kerr AT; Jacobson AE; Rice KC
    Molecules; 2024 Apr; 29(9):. PubMed ID: 38731416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A MOR Antagonist with High Potency and Antagonist Efficacy among Diastereomeric C9-Alkyl-Substituted
    Chambers DR; Sulima A; Luo D; Prisinzano TE; Jacobson AE; Rice KC
    Molecules; 2023 Jul; 28(14):. PubMed ID: 37513283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Journey through Diastereomeric Space: The Design, Synthesis, In Vitro and In Vivo Pharmacological Activity, and Molecular Modeling of Novel Potent Diastereomeric MOR Agonists and Antagonists.
    Chambers DR; Sulima A; Luo D; Prisinzano TE; Goldberg A; Xie B; Shi L; Paronis CA; Bergman J; Nassehi N; Selley DE; Imler GH; Jacobson AE; Rice KC
    Molecules; 2022 Sep; 27(19):. PubMed ID: 36234992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G-Protein biased opioid agonists: 3-hydroxy-
    Gutman ES; Bow E; Li F; Sulima A; Kaska S; Crowley R; Prisinzano TE; Lee YS; Hassan SA; Imler GH; Deschamps JR; Jacobson AE; Rice KC
    RSC Med Chem; 2020 Aug; 11(8):896-904. PubMed ID: 33479684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.
    Hiebel AC; Lee YS; Bilsky E; Giuvelis D; Deschamps JR; Parrish DA; Aceto MD; May EL; Harris LS; Coop A; Dersch CM; Partilla JS; Rothman RB; Cheng K; Jacobson AE; Rice KC
    J Med Chem; 2007 Aug; 50(16):3765-76. PubMed ID: 17625813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Pharmacological Evaluation of Enantiopure N-Substituted Ortho-c Oxide-Bridged 5-Phenylmorphans.
    Li F; Kopajtic TA; Katz JL; Luo D; Prisinzano TE; Imler GH; Deschamps JR; Jacobson AE; Rice KC
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent MOR Agonists from 2'-Hydroxy-5,9-dimethyl-
    Das M; Ward GW; Sulima A; Luo D; Prisinzano TE; Imler GH; Kerr AT; Jacobson AE; Rice KC
    Molecules; 2023 Nov; 28(23):. PubMed ID: 38067439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonists.
    Cheng K; Kim IJ; Lee MJ; Adah SA; Raymond TJ; Bilsky EJ; Aceto MD; May EL; Harris LS; Coop A; Dersch CM; Rothman RB; Jacobson AE; Rice KC
    Org Biomol Chem; 2007 Apr; 5(8):1177-1190. PubMed ID: 17406716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of opioid receptor affinity and efficacy via N-substitution of 9β-hydroxy-5-(3-hydroxyphenyl)morphan: Synthesis and computer simulation study.
    Truong PM; Hassan SA; Lee YS; Kopajtic TA; Katz JL; Chadderdon AM; Traynor JR; Deschamps JR; Jacobson AE; Rice KC
    Bioorg Med Chem; 2017 Apr; 25(8):2406-2422. PubMed ID: 28314512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.
    Zhang Y; Williams DA; Zaidi SA; Yuan Y; Braithwaite A; Bilsky EJ; Dewey WL; Akbarali HI; Streicher JM; Selley DE
    ACS Chem Neurosci; 2016 Mar; 7(3):297-304. PubMed ID: 26716358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis, and Structure-Activity Relationship Exploration of Alkyl/Phenylalkyl Piperidine Analogues as Novel Highly Potent and Selective μ Opioid Receptor Agonists.
    Huang H; Li X; Guo W; Zhu C; Qian Y; Shen Q; Xu X; Li W; Wang Y; Fu W
    ACS Chem Neurosci; 2021 Jan; 12(2):285-299. PubMed ID: 32852933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Intriguing Effects of Substituents in the
    Wang M; Irvin TC; Herdman CA; Hanna RD; Hassan SA; Lee YS; Kaska S; Crowley RS; Prisinzano TE; Withey SL; Paronis CA; Bergman J; Inan S; Geller EB; Adler MW; Kopajtic TA; Katz JL; Chadderdon AM; Traynor JR; Jacobson AE; Rice KC
    Molecules; 2020 Jun; 25(11):. PubMed ID: 32517185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of efficacy as a determinant of locomotor activation by mu-opioid receptor (MOR) ligands in female and male mice. II. Effects of novel MOR-selective phenylmorphans with high-to-low MOR efficacy.
    Santos EJ; Nassehi N; Bow EW; Chambers DR; Gutman ES; Jacobson AE; Lutz JA; Marsh SA; Rice KC; Sulima A; Selley DE; Negus SS
    Pharmacol Res Perspect; 2023 Aug; 11(4):e01111. PubMed ID: 37381112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective μ-antagonist activity.
    Iyer MR; Lee YS; Deschamps JR; Dersch CM; Rothman RB; Jacobson AE; Rice KC
    Eur J Med Chem; 2012 Apr; 50():44-54. PubMed ID: 22341895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine.
    Kaski SW; White AN; Gross JD; Trexler KR; Wix K; Harland AA; Prisinzano TE; Aubé J; Kinsey SG; Kenakin T; Siderovski DP; Setola V
    J Pharmacol Exp Ther; 2019 Nov; 371(2):487-499. PubMed ID: 31492823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphinan derivatives with an oxabicyclo[3.2.1]octane structure as dual agonists toward δ and κ opioid receptors.
    Uenohara Y; Tsumura S; Hirayama S; Higashi E; Watanabe Y; Gouda H; Nagase H; Fujii H
    Bioorg Med Chem; 2022 Jan; 53():116552. PubMed ID: 34894610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, biological, and structural explorations of a series of μ-opioid receptor (MOR) agonists with high G protein signaling bias.
    Yang Y; Wang Y; Zuo A; Li C; Wang W; Jiang W; Zhang X; Che X; Zhang Y; Wu W; Cen X; Wang H; Tian J
    Eur J Med Chem; 2022 Jan; 228():113986. PubMed ID: 34802839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.
    Vekariya RH; Lei W; Ray A; Saini SK; Zhang S; Molnar G; Barlow D; Karlage KL; Bilsky EJ; Houseknecht KL; Largent-Milnes TM; Streicher JM; Ananthan S
    J Med Chem; 2020 Jul; 63(14):7663-7694. PubMed ID: 32530286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic Characterization of Substituted Nitazenes at
    Kozell LB; Eshleman AJ; Wolfrum KM; Swanson TL; Bloom SH; Benware S; Schmachtenberg JL; Schutzer KA; Schutzer WE; Janowsky A; Abbas AI
    J Pharmacol Exp Ther; 2024 Apr; 389(2):219-228. PubMed ID: 38453524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.